Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

23 mars 2023

Poxel extended its cash runway to Q2 2025 via debt restructuring and new financing, supported by rising TWYMEEG® sales and clinical progress.

Lyon, France March 23, 2023 – Poxel extended its cash runway to Q2 2025 through debt restructuring and a new equity-linked financing with IRIS, supported by strong TWYMEEG® sales growth and positive Phase 2 NASH results while it prepares to advance rare disease programs.

Download Poxel press release